$Silo Pharma (SILO.US)$ NEWS Silo Pharma to Participate in F...
NEWS
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
Silo Pharma, a developmental stage biopharmaceutical company, will attend a hybrid public meeting hosted by the FDA and Reagan-Udall Foundation on June 27, 2024. The event, titled “Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest,” will discuss ketamine's use for treating depression and chronic pain. CEO Eric Weisblum, along with a scientific advisor, will represent Silo Pharma. The company's lead program, SPC-15, is an intranasal treatment for PTSD and anxiety, licensed exclusively from Columbia University. Additionally, Silo is developing SP-26, a ketamine-based dissolvable implant for chronic pain and fibromyalgia.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment